Viatris (WBO:MYL) ROE % Adjusted to Book Value : 3.17% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viatris ROE % Adjusted to Book Value?

Viatris's ROE % for the quarter that ended in Mar. 2024 was 2.25%. Viatris's PB Ratio for the quarter that ended in Mar. 2024 was 0.71. Viatris's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 3.17%.

Viatris ROE % Adjusted to Book Value Historical Data

The historical data trend for Viatris's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris ROE % Adjusted to Book Value Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.16

-4.01

-7.68

16.38

0.41

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															7.61	8.82	11.05	-23.27	3.17

Competitive Comparison of Viatris's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Viatris's ROE % Adjusted to Book Value falls into.

Viatris ROE % Adjusted to Book Value Calculation

Viatris's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.26%	/	0.63
	=	0.41%

Viatris's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	2.25%	/	0.71
	=	3.17%

Viatris ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Viatris's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (WBO:MYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines